Ensysce Biosciences (ENSC) EBITDA Margin (2020 - 2025)
Ensysce Biosciences' (ENSC) quarterly EBITDA Margin came in at 758.68% in Q3 2025, down 77754.0% year-over-year from N/an in Q3 2024, and down 494.39% quarter-over-quarter from 127.64% in Q2 2025.
Powered by 
Analysis
Ensysce Biosciences (ENSC) EBITDA Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported EBITDA Margin for 6 consecutive years, with 758.68% the latest figure, recorded in Q3 2025.
- On a quarterly basis, EBITDA Margin fell 77754.0% year-over-year to 758.68% in Q3 2025; TTM through Sep 2025 was 245.89%, a 10319.0% decrease from a year earlier, with the FY2024 full-year figure at 129.18%, up 35135.0% from the prior year.
- EBITDA Margin was 758.68% for Q3 2025 at Ensysce Biosciences, down from 127.64% in the prior quarter.
- Over five years, EBITDA Margin peaked at 18.86% in Q3 2024 and troughed at 3400.56% in Q2 2022.
- A 5-year average of 719.09% and a median of 467.7% in 2023 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin plunged 330774 bps in 2022 and jumped 293286 bps in 2023, its largest moves.
- Over 5 years, EBITDA Margin stood at 122.71% in 2021, then sank by 253 bps to 432.57% in 2022, then plunged by 42 bps to 612.72% in 2023, then jumped by 55 bps to 274.34% in 2024, then slumped by 177 bps to 758.68% in 2025.
- The last three EBITDA Margin figures came in at 758.68% (Q3 2025), 127.64% (Q2 2025), and 149.08% (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 42.23% |
| 10 | Ensysce Biosciences | 1.18 Mn | -3.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -758.68% |
| Jun 30, 2025 | -127.64% |
| Mar 31, 2025 | -149.08% |
| Dec 31, 2024 | -274.34% |
| Sep 30, 2024 | 18.86% |
| Jun 30, 2024 | -1,075.62% |
| Mar 31, 2024 | -602.82% |
| Dec 31, 2023 | -612.72% |
| Sep 30, 2023 | -621.83% |
| Jun 30, 2023 | -467.70% |
| Mar 31, 2023 | -324.36% |
| Dec 31, 2022 | -432.57% |
| Sep 30, 2022 | -2,206.30% |
| Jun 30, 2022 | -3,400.56% |
| Mar 31, 2022 | -796.36% |
| Dec 31, 2021 | -122.71% |
| Sep 30, 2021 | -1,406.28% |
| Jun 30, 2021 | -92.82% |
| Mar 31, 2021 | -209.23% |
| Dec 31, 2020 | -262.51% |